Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARPC5L mRNA | CTD | PMID:22079256 | 1,2-dimethylhydrazine | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of ARPC5L mRNA | CTD | PMID:22206623 | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of ARPC5L mRNA | CTD | PMID:32145629 | 2,2',4,4'-Tetrabromodiphenyl ether | affects expression | ISO | Arpc5l (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:30294300 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Arpc5l (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of ARPC5L mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of ARPC5L mRNA | CTD | PMID:34747641 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ARPC5L mRNA | CTD | PMID:19770486 | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 2,4,6-tribromophenol | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | 2 more ... | CTD | PMID:31675489 | 2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 2 and 6-dinitrotoluene affects the expression of ARPC5L mRNA | CTD | PMID:21346803 | 2-palmitoylglycerol | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | 2-palmitoylglycerol results in increased expression of ARPC5L mRNA | CTD | PMID:37199045 | 3,3',5,5'-tetrabromobisphenol A | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | tetrabromobisphenol A results in increased expression of ARPC5L protein | CTD | PMID:31675489 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARPC5L mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC5L mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | affects expression | ISO | ARPC5L (Homo sapiens) | 6480464 | bisphenol S affects the expression of ARPC5L protein | CTD | PMID:31945527 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of ARPC5L mRNA | CTD | PMID:30047161 | acrolein | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of ARPC5L mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of ARPC5L mRNA | CTD | PMID:32699268 | acrylamide | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Acrylamide results in increased expression of ARPC5L mRNA | CTD | PMID:32763439 | all-trans-retinoic acid | decreases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of ARPC5L mRNA | CTD | PMID:33167477 | alpha-pinene | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of ARPC5L mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of ARPC5L mRNA | CTD | PMID:32699268 | amitrole | increases expression | EXP | | 6480464 | Amitrole results in increased expression of ARPC5L mRNA | CTD | PMID:30047161 | aristolochic acid A | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | aristolochic acid I results in increased expression of ARPC5L mRNA | CTD | PMID:33212167 | arsane | affects methylation | ISO | ARPC5L (Homo sapiens) | 6480464 | Arsenic affects the methylation of ARPC5L gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | ARPC5L (Homo sapiens) | 6480464 | Arsenic affects the methylation of ARPC5L gene | CTD | PMID:25304211 | arsenite(3-) | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to ARPC5L mRNA] | CTD | PMID:32406909 | arsenous acid | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | Arsenic Trioxide results in decreased expression of ARPC5L mRNA | CTD | PMID:29095437 | arsenous acid | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | Metformin inhibits the reaction [Arsenic Trioxide results in decreased expression of ARPC5L mRNA] | CTD | PMID:29095437 | benzo[a]pyrene | increases expression | ISO | Arpc5l (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of ARPC5L mRNA | CTD | PMID:22228805 | benzo[a]pyrene diol epoxide I | affects expression | ISO | ARPC5L (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20382639 | bisphenol A | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | bisphenol A results in decreased expression of ARPC5L mRNA | CTD | PMID:26063408 | bisphenol A | decreases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of ARPC5L protein | CTD | PMID:31675489 | bisphenol A | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARPC5L mRNA | CTD | PMID:28628672 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of ARPC5L mRNA | CTD | PMID:25181051 and PMID:32145629 | bisphenol F | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC5L mRNA | CTD | PMID:28628672 | bisphenol F | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | bisphenol F results in increased expression of ARPC5L protein | CTD | PMID:34186270 | butanal | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | butyraldehyde results in increased expression of ARPC5L mRNA | CTD | PMID:26079696 | casticin | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | casticin results in decreased expression of ARPC5L mRNA | CTD | PMID:28444820 | chlorpyrifos | decreases expression | EXP | | 6480464 | Chlorpyrifos results in decreased expression of ARPC5L mRNA | CTD | PMID:18668222 | choline | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ARPC5L gene | CTD | PMID:20938992 | copper(II) sulfate | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of ARPC5L mRNA | CTD | PMID:19549813 | decabromodiphenyl ether | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | decabromobiphenyl ether results in increased expression of ARPC5L protein | CTD | PMID:31675489 | dexamethasone | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARPC5L mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC5L mRNA | CTD | PMID:28628672 | diarsenic trioxide | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | Arsenic Trioxide results in decreased expression of ARPC5L mRNA | CTD | PMID:29095437 | diarsenic trioxide | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | Metformin inhibits the reaction [Arsenic Trioxide results in decreased expression of ARPC5L mRNA] | CTD | PMID:29095437 | diazinon | increases methylation | ISO | ARPC5L (Homo sapiens) | 6480464 | Diazinon results in increased methylation of ARPC5L gene | CTD | PMID:22964155 | dicrotophos | decreases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of ARPC5L mRNA | CTD | PMID:28302478 | diethylstilbestrol | decreases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Diethylstilbestrol results in decreased expression of ARPC5L mRNA | CTD | PMID:36621641 | finasteride | increases expression | EXP | | 6480464 | Finasteride results in increased expression of ARPC5L mRNA | CTD | PMID:24136188 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of ARPC5L mRNA | CTD | PMID:24136188 | folic acid | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | [1 more ... | CTD | PMID:20938992 and PMID:22206623 | FR900359 | increases phosphorylation | ISO | ARPC5L (Homo sapiens) | 6480464 | FR900359 results in increased phosphorylation of ARPC5L protein | CTD | PMID:37730182 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of ARPC5L mRNA | CTD | PMID:22061828 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of ARPC5L mRNA | CTD | PMID:33387578 | glafenine | increases expression | EXP | | 6480464 | Glafenine results in increased expression of ARPC5L mRNA | CTD | PMID:24136188 | indometacin | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARPC5L mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC5L mRNA | CTD | PMID:28628672 | ivermectin | decreases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of ARPC5L protein | CTD | PMID:32959892 | L-methionine | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ARPC5L gene | CTD | PMID:20938992 | metformin | multiple interactions | ISO | Arpc5l (Mus musculus) | 6480464 | Metformin inhibits the reaction [Arsenic Trioxide results in decreased expression of ARPC5L mRNA] | CTD | PMID:29095437 | methimazole | increases expression | EXP | | 6480464 | Methimazole results in increased expression of ARPC5L mRNA | CTD | PMID:30047161 | N-methyl-4-phenylpyridinium | increases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of ARPC5L mRNA | CTD | PMID:28801915 | nefazodone | increases expression | EXP | | 6480464 | nefazodone results in increased expression of ARPC5L mRNA | CTD | PMID:24136188 | nickel atom | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Nickel results in increased expression of ARPC5L mRNA | CTD | PMID:25583101 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of ARPC5L mRNA | CTD | PMID:24136188 | ozone | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of ARPC5L mRNA more ... | CTD | PMID:32699268 | pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of ARPC5L mRNA | CTD | PMID:19162173 | potassium chromate | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | potassium chromate(VI) results in increased expression of ARPC5L mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARPC5L mRNA | CTD | PMID:22079256 | resveratrol | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | resveratrol results in decreased expression of ARPC5L protein | CTD | PMID:25505154 | sarin | increases expression | EXP | | 6480464 | Sarin results in increased expression of ARPC5L protein | CTD | PMID:28973502 | saxitoxin | decreases expression | ISO | Arpc5l (Mus musculus) | 6480464 | Saxitoxin results in decreased expression of ARPC5L protein | CTD | PMID:29228856 | sulfadimethoxine | increases expression | EXP | | 6480464 | Sulfadimethoxine results in increased expression of ARPC5L mRNA | CTD | PMID:30047161 | triptonide | increases expression | ISO | Arpc5l (Mus musculus) | 6480464 | triptonide results in increased expression of ARPC5L mRNA | CTD | PMID:33045310 | valproic acid | increases expression | ISO | ARPC5L (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of ARPC5L mRNA | CTD | PMID:23179753 | zinc atom | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of ARPC5L mRNA | CTD | PMID:18593933 | zinc(0) | multiple interactions | ISO | ARPC5L (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of ARPC5L mRNA | CTD | PMID:18593933 | |